Investors may find better financial performance in Immunic Inc (IMUX)

Ulysses Smith

A share price of Immunic Inc [IMUX] is currently trading at $0.78, up 2.04%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMUX shares have gain 12.85% over the last week, with a monthly amount drifted -12.82%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Immunic Inc [NASDAQ: IMUX] stock has seen the most recent analyst activity on November 07, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $3. Previously, Chardan Capital Markets started tracking the stock with Buy rating on September 29, 2025, and set its price target to $13. On March 25, 2025, William Blair initiated with a Outperform rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $10 on November 25, 2024. B. Riley Securities started tracking with a Buy rating for this stock on August 27, 2024, and assigned it a price target of $6. In a note dated October 21, 2022, SVB Leerink downgraded an Mkt Perform rating on this stock but restated the target price of $5.

Immunic Inc experienced fluctuations in its stock price throughout the past year between $0.56 and $1.42. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.78 at the most recent close of the market. An investor can expect a potential return of 541.03% based on the average IMUX price forecast.

Analyzing the IMUX fundamentals

Gross Profit Margin for this corporation currently stands at -0.62% with Operating Profit Margin at -923.38%, Pretax Profit Margin comes in at -893.3%, and Net Profit Margin reading is -893.3%. To continue investigating profitability, this company’s Return on Assets is posted at -1.66, Equity is -4.61 and Total Capital is -3.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7619 points at the first support level, and at 0.7440 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7889, and for the 2nd resistance point, it is at 0.7980.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Immunic Inc [NASDAQ:IMUX] is 2.19. As well, the Quick Ratio is 2.19, while the Cash Ratio is 2.03.

Transactions by insiders

Recent insider trading involved Nash Duane, Executive Chairman, that happened on Jun 13 ’25 when 20000.0 shares were purchased. President and COO, Tardio Jason completed a deal on Jun 05 ’25 to buy 12512.0 shares. Meanwhile, CEO and Director Vitt Daniel bought 15000.0 shares on Jun 04 ’25.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.